Population Pharmacokinetic and Exposure-Response Models for Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus

Immunology

Pharmacometrics

PAGE 29 (2021) Abstr 9884.

Acharya C, Magnusson MO, Vajjah P, Zamacona M